← Browse by Condition
Medical Condition
leukemia
Total Trials
15
Recruiting Now
15
Trial Phases
Phase 2, Phase 1, Phase 2, Phase 1
Leukemia clinical trials cover acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL) — distinct diseases with profoundly different biology and treatment approaches. AML research focuses on targeted agents for FLT3, IDH1/2, and TP53-mutated disease, while CLL trials explore fixed-duration venetoclax combinations that achieve treatment-free remissions.
Active trials investigate menin inhibitors for NPM1/KMT2A AML, magrolimab (anti-CD47) combinations, bispecific antibodies in relapsed ALL, and next-generation BTK inhibitors (pirtobrutinib) for ibrutinib-resistant CLL. MRD (minimal residual disease) negativity is emerging as a regulatory endpoint to accelerate approvals.
Frequently Asked Questions — leukemia Clinical Trials
How many clinical trials are currently recruiting for leukemia?
ClinicalMetric currently tracks 15 actively recruiting clinical trials for leukemia, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 15. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for leukemia?
leukemia research spans Phase 1 (6 trials), Phase 2 (7 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a leukemia clinical trial?
Eligibility criteria for leukemia trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 6
Phase 2 7
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT00582621
Recruiting
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Enrollment
500 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
NCT07105579 Phase 2
Recruiting
Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia
Enrollment
31 pts
Location
China
Sponsor
First Affiliated Hospital of Z...
NCT03319901 Phase 1, Phase 2
Recruiting
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
Enrollment
82 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
NCT06839456 Phase 1, Phase 2
Recruiting
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Enrollment
100 pts
Location
United States
Sponsor
Children's Hospital of Philade...
NCT07052695 Phase 1, Phase 2
Recruiting
Mosunetuzumab for CLL MRD Clearance
Enrollment
40 pts
Location
United States
Sponsor
Inhye Ahn
NCT07294677 Phase 1, Phase 2
Recruiting
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
Enrollment
104 pts
Location
United States
Sponsor
University of Chicago
NCT06824168 Phase 2
Recruiting
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Enrollment
130 pts
Location
United States, Austr...
Sponsor
Daiichi Sankyo
NCT05691608
Recruiting
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
Enrollment
1,800 pts
Location
France
Sponsor
Gustave Roussy, Cancer Campus,...
NCT00935090
Recruiting
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Location
United States
Sponsor
Barbara Ann Karmanos Cancer In...
NCT05528887 Phase 1
Recruiting
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
Enrollment
10 pts
Location
China
Sponsor
The Affiliated People's Hospit...
NCT06250595
Recruiting
European Rare Blood Disorders Platform (ENROL)
Enrollment
37,090 pts
Location
Spain
Sponsor
Hospital Universitari Vall d'H...
NCT05062707
Recruiting
Early Ageing During Therapy in AYA Cancer Patients
Enrollment
120 pts
Location
Netherlands
Sponsor
University Medical Center Gron...
NCT07205523
Recruiting
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
Enrollment
1,000 pts
Location
China
Sponsor
Yigeng Cao,MD,PhD
NCT03452774
Recruiting
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Enrollment
50,000 pts
Location
United States, Puert...
Sponsor
Massive Bio, Inc.
NCT05673057 Phase 1, Phase 2
Recruiting
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
Enrollment
249 pts
Location
France, Lithuania, N...
Sponsor
Molecular Partners AG
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology